Evotec (EVO) Competitors $4.44 -0.02 (-0.45%) Closing price 04:00 PM EasternExtended Trading$4.42 -0.02 (-0.34%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends EVO vs. AXSM, BPMC, TLX, ELAN, LNTH, NUVL, CYTK, VRNA, GRFS, and TGTXShould you be buying Evotec stock or one of its competitors? The main competitors of Evotec include Axsome Therapeutics (AXSM), Blueprint Medicines (BPMC), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Elanco Animal Health (ELAN), Lantheus (LNTH), Nuvalent (NUVL), Cytokinetics (CYTK), Verona Pharma (VRNA), Grifols (GRFS), and TG Therapeutics (TGTX). These companies are all part of the "pharmaceutical products" industry. Evotec vs. Axsome Therapeutics Blueprint Medicines Telix Pharmaceuticals Limited American Depositary Shares Elanco Animal Health Lantheus Nuvalent Cytokinetics Verona Pharma Grifols TG Therapeutics Evotec (NASDAQ:EVO) and Axsome Therapeutics (NASDAQ:AXSM) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, media sentiment, valuation, community ranking, dividends and analyst recommendations. Do analysts prefer EVO or AXSM? Evotec currently has a consensus target price of $5.93, indicating a potential upside of 33.63%. Axsome Therapeutics has a consensus target price of $157.64, indicating a potential upside of 14.44%. Given Evotec's higher probable upside, equities analysts clearly believe Evotec is more favorable than Axsome Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evotec 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Axsome Therapeutics 0 Sell rating(s) 0 Hold rating(s) 15 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor EVO or AXSM? In the previous week, Axsome Therapeutics had 53 more articles in the media than Evotec. MarketBeat recorded 55 mentions for Axsome Therapeutics and 2 mentions for Evotec. Evotec's average media sentiment score of 0.58 beat Axsome Therapeutics' score of 0.46 indicating that Evotec is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evotec 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Axsome Therapeutics 12 Very Positive mention(s) 4 Positive mention(s) 19 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders believe in EVO or AXSM? 5.8% of Evotec shares are held by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are held by institutional investors. 1.0% of Evotec shares are held by insiders. Comparatively, 22.4% of Axsome Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the MarketBeat Community favor EVO or AXSM? Axsome Therapeutics received 464 more outperform votes than Evotec when rated by MarketBeat users. Likewise, 70.25% of users gave Axsome Therapeutics an outperform vote while only 54.55% of users gave Evotec an outperform vote. CompanyUnderperformOutperformEvotecOutperform Votes654.55% Underperform Votes545.45% Axsome TherapeuticsOutperform Votes47070.25% Underperform Votes19929.75% Which has preferable earnings and valuation, EVO or AXSM? Evotec has higher revenue and earnings than Axsome Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvotec$845.74M1.86-$90.82MN/AN/AAxsome Therapeutics$385.69M17.41-$239.24M-$5.99-23.00 Which has more risk and volatility, EVO or AXSM? Evotec has a beta of 1.45, meaning that its stock price is 45% more volatile than the S&P 500. Comparatively, Axsome Therapeutics has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500. Is EVO or AXSM more profitable? Evotec has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -74.47%. Evotec's return on equity of 0.00% beat Axsome Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets EvotecN/A N/A N/A Axsome Therapeutics -74.47%-223.51%-39.88% SummaryEvotec and Axsome Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Get Evotec News Delivered to You Automatically Sign up to receive the latest news and ratings for EVO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EVO vs. The Competition Export to ExcelMetricEvotecPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.57B$7.05B$5.80B$8.95BDividend YieldN/A2.87%4.78%3.85%P/E RatioN/A6.1126.4518.81Price / Sales1.86313.84450.0676.66Price / Cash159.6367.8344.0437.47Price / Book1.306.747.634.64Net Income-$90.82M$138.11M$3.18B$245.69M7 Day Performance-3.06%-2.04%-1.85%-2.63%1 Month Performance7.51%-1.57%0.19%-2.37%1 Year Performance-39.51%-3.19%17.21%13.64% Evotec Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EVOEvotec1.8117 of 5 stars$4.44-0.4%$5.93+33.6%-39.6%$1.57B$845.74M0.005,061AXSMAxsome Therapeutics4.5395 of 5 stars$131.15-0.4%$147.13+12.2%+59.2%$6.36B$270.60M-20.08380Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageBPMCBlueprint Medicines3.0196 of 5 stars$93.94-1.3%$123.83+31.8%+3.4%$5.97B$249.38M-44.52640Earnings ReportTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$17.19-0.6%$22.00+28.0%N/A$5.79B$637.08M0.00N/ANews CoverageGap UpELANElanco Animal Health4.1542 of 5 stars$11.26-3.4%$16.29+44.7%-31.0%$5.57B$4.42B28.159,300Analyst ForecastLNTHLantheus4.588 of 5 stars$79.94-2.5%$131.86+64.9%+42.3%$5.56B$1.30B13.30700Analyst RevisionNUVLNuvalent2.126 of 5 stars$77.93-3.7%$112.36+44.2%+0.5%$5.54BN/A-22.4640Upcoming EarningsInsider TradeCYTKCytokinetics4.2215 of 5 stars$46.16+10.9%$82.00+77.6%-33.5%$5.45B$7.53M-8.58250High Trading VolumeVRNAVerona Pharma1.9573 of 5 stars$64.21+4.1%$57.14-11.0%+277.6%$5.13B$460,000.00-33.4430GRFSGrifols2.1748 of 5 stars$7.32-2.0%N/A-11.8%$5.03B$7.13B6.2023,737TGTXTG Therapeutics4.4888 of 5 stars$30.71-0.1%$40.67+32.4%+133.9%$4.78B$233.66M-307.07290Positive News Related Companies and Tools Related Companies Axsome Therapeutics Alternatives Blueprint Medicines Alternatives Telix Pharmaceuticals Limited American Depositary Shares Alternatives Elanco Animal Health Alternatives Lantheus Alternatives Nuvalent Alternatives Cytokinetics Alternatives Verona Pharma Alternatives Grifols Alternatives TG Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:EVO) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evotec SE Please log in to your account or sign up in order to add this asset to your watchlist. Share Evotec With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
